Clinical trial of TPX-0005 from TP Therapeutics

As of March 6, 2017, lists a Trial of TPX-0005 which targets ALK, ROS1, and NTRK 1-3. At this time there are four trial sites at: UC Irvine Cancer center, University of Colorado, Denver, Massachusetts General Hospital, and Memorial Sloan Kettering.

The trial does cover patients with regular body measurable mets and only measurable brain mets.

The trial identifier is NCT03093116.

This entry was posted in Brain metastases, Lung cancer, Potential Treatments, Research, TPX-0005: TP Therapeutics. Bookmark the permalink.

Leave a Reply